Openfund

CORDIS · TransBioNet

Accelerating Biomedical Translation through a European Network of Knowledge Valorisation Intermediaries

Код
TransBioNet
Програма
HORIZON
Процедура
VALLEYS Open Call #1 HORIZON-WIDERA-2025-06-ERA-01
Статус
SIGNED
Период
01.09.2026 – 31.08.2029
Обща стойност (целият консорциум)1 964 375 €
Принос на ЕС (целият консорциум)1 964 375 €
Принос на ЕС за българските участници187 875 €

Официални данни · CORDIS · синхронизирано 17.10.2026 10:16 · официален запис

Участници

ОрганизацииРоляДържаваБезвъзмездна помощ
Associação AccelbioкоординаторPT586 000 €
EATRIS ERICучастникNL342 500 €
EIT HEALTH INNOSTARS EVучастникDE279 000 €
FORENINGEN DANISH LIFE SCIENCE CLUSTERучастникDK229 312 €
BIOTEHNOLOGICHEN I ZDRAVEN KLASTERучастникBG187 875 €
ASOCIACIJA LITHUANIABIOучастникLT173 250 €
BIOCANT PARK, S.A.участникPT166 438 €

Описание

TransBioNet will establish the first pan-European network of knowledge valorisation intermediaries fully dedicated to drug discovery and biomedical innovation. Despite Europe’s world-class science, promising discoveries often fail to reach patients due to fragmented support, under-recognised intermediaries, and limited cross-border collaborations. TransBioNet addresses this gap by connecting regional clusters, pan-European infrastructures, and accelerators into a coherent ecosystem that equips intermediaries with harmonised tools, training, and services. The project will deliver three flagship resources: (i) the TransBioNet Digital Platform, a central hub integrating the Infrastructure Atlas, matchmaking tools, and training modules; (ii) a Valorisation Assessment Toolkit, providing standardised TRL/IRL evaluations embedding regulatory, IP, and market dimensions; and (iii) the TransBioNet Charter, a policy framework to ensure recognition of intermediaries across EU and national innovation strategies. Two Open Calls will support 12 early-stage drug discovery projects with mentoring, bootcamps, and access to infrastructures, creating tangible case studies of valorisation in practice. Through training programmes, secondments, and a Community of Practice, the project will build a new generation of skilled intermediaries able to de-risk biomedical projects, improve reproducibility, and accelerate translation. By lowering attrition rates and increasing investment readiness, TransBioNet will strengthen Europe’s competitiveness in drug discovery while ensuring inclusive participation of less-resourced regions. The project directly advances ERA Action 7 on Knowledge Valorisation, reinforcing open science, responsible research assessment, and cross-border collaboration. By its conclusion, TransBioNet will deliver a recognised European reference point for biomedical valorisation, ensuring that high-quality science translates into innovative therapies, jobs & societal impact.

Официални данни · CORDIS · синхронизирано 17.10.2026 10:16 · официален запис · Лиценз: © European Union, CC BY 4.0 (Commission reuse policy).